Atrys Health S.A [ATRY] vs Oryzon Genomics S.A [ORY] Detailed Stock Comparison

Atrys Health S.A.

BME
Loading...

Oryzon Genomics S.A.

BME
Loading...

TLDR: Quick Comparison Summary

Based on 17 vital metrics comparison: Atrys Health S.A. wins in 8 metrics, Oryzon Genomics S.A. wins in 8 metrics, with 0 ties. Both stocks appear equally matched on key metrics.

View Metrics Details

Vital Metrics Comparison

Metric Atrys Health S.A. Oryzon Genomics S.A. Better
Price-to-Book Ratio 1.48 1.85 Atrys Health S.A.
Debt-to-Equity Ratio 155.00 15.07 Oryzon Genomics S.A.
PEG Ratio 27.91 55.92 Atrys Health S.A.
EV/EBITDA 24.52 -37.27 Atrys Health S.A.
Profit Margin (TTM) -69.50% -23.83% Oryzon Genomics S.A.
Operating Margin (TTM) -36.65% 53.04% Oryzon Genomics S.A.
EBITDA Margin (TTM) N/A 53.04% N/A
Return on Equity -27.46% -2.53% Oryzon Genomics S.A.
Return on Assets (TTM) -1.05% -2.81% Atrys Health S.A.
Free Cash Flow (TTM) $-14.08M $-13.40M Oryzon Genomics S.A.
1-Year Return 1.75% 2.95% Oryzon Genomics S.A.
Price-to-Sales Ratio (TTM) 1.55 20.26 Atrys Health S.A.
Enterprise Value $446.08M $208.60M Atrys Health S.A.
EV/Revenue Ratio 3.09 19.08 Atrys Health S.A.
Revenue per Share (TTM) $2 $0 Atrys Health S.A.
Earnings per Share (Diluted) $-0.73 $-0.03 Oryzon Genomics S.A.
Beta (Stock Volatility) 0.56 0.44 Oryzon Genomics S.A.

Atrys Health S.A. vs Oryzon Genomics S.A. Stock Performance Analysis

Loading Price Chart...

ATRY
ORY

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Atrys Health S.A.0.52%-3.65%7.41%-3.65%-14.20%-0.68%
Oryzon Genomics S.A.-1.34%-3.13%0.72%-12.81%-12.81%-13.35%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Atrys Health S.A.1.75%-42.91%-69.15%81.25%81.25%81.25%
Oryzon Genomics S.A.2.95%31.60%-21.41%-5.42%-21.41%-21.41%

Performance & Financial Health Analysis: Atrys Health S.A. vs Oryzon Genomics S.A.

MetricATRYORY
Market Information
Market Cap i€222.81M€220.00M
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i119,174235,645
90 Day Avg. Volume i68,275275,214
Last Close€2.90€2.79
52 Week Range€2.48 - €3.59€2.51 - €4.02
% from 52W High-19.08%-30.60%
All-Time High€11.25 (Aug 30, 2021)€5.25 (Dec 14, 2015)
% from All-Time High-74.22%-46.86%
Growth Metrics
Quarterly Revenue Growth-0.75%0.49%
Quarterly Earnings GrowthN/AN/A
Financial Health
Profit Margin (TTM) i-0.70%-0.24%
Operating Margin (TTM) i-0.37%0.53%
Return on Equity (TTM) i-0.27%-0.03%
Debt to Equity (MRQ) i155.0015.07
Cash & Liquidity
Book Value per Share (MRQ)€2.00€1.52
Cash per Share (MRQ)€0.23€0.37
Operating Cash Flow (TTM) i€-1,559,000€-2,356,163
Levered Free Cash Flow (TTM) i€-123,750,376€-11,863,420
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Atrys Health S.A. vs Oryzon Genomics S.A.

MetricATRY (Apr 21, 2026)ORY (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/AN/A
Forward P/E i27.9155.92
PEG Ratio i27.9155.92
Price to Sales (TTM) i1.5520.26
Price to Book (MRQ) i1.481.85
Market Capitalization
Market Capitalization i€222.81M€220.00M
Enterprise Value i€446.08M€208.60M
Enterprise Value Metrics
Enterprise to Revenue i3.0919.08
Enterprise to EBITDA i24.52-37.27
Risk & Other Metrics
Beta i0.560.44
Book Value per Share (MRQ) i€2.00€1.52

Financial Statements Comparison: Atrys Health S.A. vs Oryzon Genomics S.A.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricATRY (2025)ORY (2025)
Revenue/Sales i141.01M0
Cost of Goods Sold i79.66M-10.65M
COGS % of Revenue i56.5%-
Gross Profit i61.35M10.65M
Gross Margin i43.5%-
Research & Development iN/AN/A
Operating Income (EBIT) i-5.74M-5.71M
Operating Margin i-4.1%-
EBITDA i22.14M-4.81M
EBITDA Margin i15.7%-
Pre-Tax Income i-56.20M-5.60M
Pre-Tax Income % of Revenue i-39.9%-
Income Tax i-576,000-2.99M
Income Tax % of Revenue i-0.4%-
Net Income (Profit) i-100.55M-2.61M
Profit Margin i-71.3%-

Balance Sheet & Liquidity Metrics

MetricATRY (2025)ORY (2025)
Cash & Equivalents i13.07M28.35M
Total Current Assets i233.96M30.67M
Total Current Assets % of Revenue i165.9%-
Total Current Liabilities i290.42M15.77M
Total Current Liabilities % of Revenue i206.0%-
Long-Term Debt i33.96M3.08M
Long-Term Debt % of Revenue i24.1%-
Total Shareholders Equity i151.96M117.85M
Retained Earnings i-100.30M-20.81M
Retained Earnings % of Revenue i-71.1%-
Property, Plant & Equipment i5.07M1.16M

Cash Flow Statement Comparison

MetricATRY (2025)ORY (2025)
Operating Cash Flow i-87.71M-6.19M
Operating Cash Flow % of Revenue i-62.2%-
Capital Expenditures i-6.49M-59,394
Free Cash Flow i-14.08M-13.40M
FCF Margin i-10.0%-
Debt Repayment i-11.60M-11.37M
Common Stock Repurchase i-36,0000

Short Interest & Institutional Ownership Analysis

MetricATRYORY
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i75.92M77.51M
Float Shares i41.72M60.52M
% Held by Insiders i54.56%21.27%
% Held by Institutions i4.54%0.75%
% Held by Public i40.90%77.98%

Dividend Analysis & Yield Comparison: Atrys Health S.A. vs Oryzon Genomics S.A.

MetricATRYORY
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A